Table 3.

MAIC results for safety outcomes

	Risk difference (regorafenib vs. cabozantinib)
	%	95% CI
Dose reductions	−15.2	−29.0, −1.5
Treatment-related AE, leading to discontinuation	−9.2	−17.7, −0.6
Grade 3 or 4 TEAEs occurring in ≥10% of patients
AST increased	−2.3	−10.7, 6.1
Diarrhea	−7.1	−14.7, 0.4
Fatigue	−6.3	−14.6, 2.0
HFSR/PPE	−0.9	−7.8, 5.9
Hypertension	−1.9	−11.4, 7.7

Data are from the safety population of each trial. AE, adverse event; AST, aspartate aminotransferase; HFSR, hand–foot skin reaction; MAIC, matching-adjusted indirect comparison; CI, confidence interval; PPE, palmar–plantar erythrodysesthesia; TEAE, treatment-emergent adverse event.